Colonics
About Me
Recent Posts
- World TB Day - Canada's Leading The International Fight Against TB, But More Work Must Be Done In Canada's North
- CytoDyn commences full humanization of Cytolin immune therapy for treating HIV/AIDS
- Access MediQuip enhances Recall Management Service for implantable devices
- Biomoda enters into agreements with syndicate of institutional investors for up to $2.0M
- Alkermes initiates multidose Phase 1 clinical study of ALKS 37 for OIC
Menu
Calendar
| Mon | Tue | Wed | Thu | Fri | Sat | Sun |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 |
| 8 | 9 | 10 | 11 | 12 | 13 | 14 |
| 15 | 16 | 17 | 18 | 19 | 20 | 21 |
| 22 | 23 | 24 | 25 | 26 | 27 | 28 |
| 29 | 30 | 31 | ||||
Friends
Links
Entry 1 of 1165
Last Page | Next Page
6/28/2008
-
Thallion Receives Health Canada Approval To Initiate Phase II Study For TLN-232 In Metastatic Melanoma Patients
|
Thallion Pharmaceuticals Inc. (TSX:TLN) announced it has conventional leave from the Therapeutic stock Directorate of Health Canada to initiate a Phase II clinical trial evaluating TLN-232 as a regimen for metastatic melanoma in next that have failed at least one prior therapy. The TLN-232 trial is the second Phase II study to be initiated this year from Thallion's oncology pipeline. More: - Read the rest here |
Post A Comment! :: Send to a Friend! |
Share and enjoy
